WO2017162092A1 - 基于表达HBsAg和HBcAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗 - Google Patents
基于表达HBsAg和HBcAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗 Download PDFInfo
- Publication number
- WO2017162092A1 WO2017162092A1 PCT/CN2017/076936 CN2017076936W WO2017162092A1 WO 2017162092 A1 WO2017162092 A1 WO 2017162092A1 CN 2017076936 W CN2017076936 W CN 2017076936W WO 2017162092 A1 WO2017162092 A1 WO 2017162092A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- hbsag
- recombinant
- hansenula
- therapeutic vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/165—Yeast isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01023—Orotidine-5'-phosphate decarboxylase (4.1.1.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/78—Hansenula
Definitions
- Hepatitis B therapeutic vaccine based on inactivated and fully recombinant Hansenula cells expressing HBsAg and HBcAg
- the invention belongs to the field of genetic engineering and relates to a vaccine for inactivating fully recombinant Hansenula cells expressing HBsAg and HBcAg for treating hepatitis B vaccine. Background technique
- Hepatitis B virus (HBV) infection is a serious public health problem.
- WHO World Health Organization
- HBV World Health Organization
- 3 billion of the world's 6 billion people have been infected with HBV, of which 350 million are chronic HBV infections, and about 1 million people die each year from livers caused by HBV infection.
- China is a endemic area of HBV infection.
- the Ministry of Health of China incorporated hepatitis B vaccine into planned immunization management in 1992.
- hepatitis B surface antigen (HBsAg) in the whole population has dropped from 9.75% in 1992 to 7.18%.
- HBsAg hepatitis B surface antigen carrying rate of children under 5 years old has been From 9.67% to 0.96%.
- Hepatitis B vaccine immunization prevention and treatment is the most effective way to reduce the burden of disease.
- HBsAg VLP virus-like particle hepatitis B surface antigen
- the pathogenesis of hepatitis B identified according to the prior art is as follows: after human infection with HBV, it can generally be divided into an immune tolerance period, an immune clearance period, and an inactive or low (non-) replication period.
- the immune tolerance period is characterized by active HBV replication, positive HBsAg and HBeAg, high HBV DNA titer (> 10 5 copies/ml), and normal serum alanine aminotransferase (ALT) levels. There was no obvious abnormality in liver histology.
- the immune clearance period is characterized by serum HBV DNA titer > 10 5 copies/ml, but generally lower than the immune tolerance period, aspartate aminotransferase (AST) is continuously or intermittently elevated, and liver histology has necrotic inflammation.
- Inactive or low (; non;) replication period showed HBeAg-negative, anti-HBe-positive, HBV DNA undetectable (PCR) method or lower than the lower limit of detection, normal levels, no obvious inflammation of liver histology.
- HBV infection in adolescents and adults, generally no immune tolerance period is the initial stage of immune clearance, manifested as acute hepatitis B, of which only 5%-10% develop chronic. However, its exact pathogenesis is still unknown.
- Anti-hepatitis B virus treatment is currently the main treatment for hepatitis B virus infection and hepatitis B patients.
- anti-hepatitis B virus drugs mainly include interferon-based immunomodulators and nucleotide analogues against HBV DNA polymerase. Although they have certain curative effects, they are not satisfactory, and most patients cannot be cured. Although interferon can make HBsAg disappear or serological transformation in a small number of patients, it is expensive, requires injection, and has certain side effects. Nucleotide analogs act on HBV DNA polymerase, which can only inhibit viral replication and cannot completely eliminate HBV. And cccDNA, and long-term application is likely to lead to viral resistance mutations.
- HBV Hepatitis B virus
- CHB chronic hepatitis B
- HBV immune tolerance is not only reflected in the liver local anti-HBV immune response can not effectively eliminate the virus, leading to persistent infection; also reflected in the persistence of HBV, and then induce the systemic immune system to respond to HBV, such as HBV-tolerant patients to HBsAg vaccine No response. This is also the main reason why current therapeutic vaccines are difficult to succeed in CHB patients. Liver-induced immune tolerance and its reversal mechanism will provide a theoretical basis for the development of hepatitis B vaccine.
- HBV antigen encounters immunity-induced efficient primary activation of HBV CTLs in the lymph nodes outside the liver, and then into the liver, which also increases the number of surviving CTLs, more effective CTLs, and also leads to liver immune response, clearing infected HBV.
- This immune mechanism for the two sites provides a theoretical basis for the development of subcutaneous, intramuscular injection of hepatitis B vaccine, which leads to liver immune response and HBV clearance.
- the GS4774 has been designated as a therapeutic vaccine for hepatitis B, and the other expressed HBV antigen is an xs-core antigen as a fusion protein.
- This yeast vector can provide a variety of antigens into the MHC class I and class II antigen presentation pathways, stimulating potent CD4+ and CD8+ cell responses. And can break the tolerance of antigens in immunological mouse models.
- the yeast vector is also not easily neutralized in the body, and is therefore suitable for repeated administration to obtain long-term immunological stress, ideally eliminating chronic intracellular infections such as HCV and P HBV.
- ⁇ -glucan particles purified from the cell wall of S. cerevisiae, which has 1,3-D-glucan polymer >85%, 2% chitin, 1% lipids and protein, and Most of the rest is ash and moisture.
- OVA ovalbumin
- GP-OVA hollow GPS shell
- free OVA was used as a control antigen.
- GPS-OVA stimulated ⁇ - ⁇ or ⁇ - ⁇ ⁇ cell proliferation in a concentration range from 0.03 to 0.5 ⁇ g/ml; conversely, free OVA failed to stimulate OT-I or ⁇ - ⁇ T cell proliferation.
- Viral-like particle GPS is a highly potent agonist of the Dectin-1 receptor
- the virus-like particle GP-OVA delivers an antigen that is more DCs (dendritic cells) than the free OVA antigen. Process and present efficiently.
- cccDNA clearance is a two-step process mediated by cellular immune responses: Cell damage is reduced by more than 90% of the pool of cccDNA molecules, thereby eliminating the precursor of HBV-relaxed circular deoxyribonucleic acid. The second step increases the process of destroying infected hepatocytes and triggers immune reversal.
- HBV was continuously carried by hydrodynamic method to simulate the immune tolerance status of chronically infected HBV patients. It was found that IL-12 pretreatment was co-injected with IL-12 and HBsAg VLP vaccine. The combination of treatment, called IL-12-based vaccine therapy, can effectively reverse HBV systemic immune tolerance, which in turn leads to HBV clearance. It was found that HBV mice experienced significant expansion of follicular-like helper T cells (Tfh) and germinal center B cells (GC B) in lymph nodes after undergoing IL-12-based vaccine therapy, corresponding to spleen cells. HBsAg-specific IgG-producing cells were also significantly increased.
- Tfh follicular-like helper T cells
- GC B germinal center B cells
- mice showed protective antibody anti-HBs in the serum of the late treatment.
- proliferation ability of sputum cells to HBsAg stimuli in vitro was also significant after IL-12 combination vaccine treatment. restore.
- a hepatitis B therapeutic vaccine having better curative effect is provided, and the technical scheme adopted by the present invention is:
- a hepatitis B therapeutic vaccine based on inactivated fully recombinant Hansenula cells expressing HBsAg and HBcAg, characterized in that: the hepatitis B therapeutic vaccine uses HBsAg and HBcAg expressed in recombinant Hansenula cells as an antigen; and contains 19 HBsAg A specific CTL epitope and 19 HBcAg-specific CTL epitopes; the hepatitis B therapeutic vaccine is adjuvanted with heat-killed recombinant Hansenula fine.
- the hepatitis B therapeutic vaccine is characterized in that the HBsAg expressed by the recombinant Hansenula is an adw subtype, and the DNA sequence of the recombinant Hansenula expressing HBsAg is as shown in SEQ ID NO: 1; the recombinant Hansenula expression HBsAg The amino acid sequence is shown as SEQ ID NO: 2.
- the hepatitis B therapeutic vaccine is characterized in that the DNA sequence of the recombinant Hansenula expressing HBcAg is represented by SEQ ID NO: 3; the amino acid sequence of the recombinant Hansenula expressing HBcAg is as shown in SEQ ID NO: 4. .
- the hepatitis B therapeutic vaccine is characterized in that the HBsAg expressed by the recombinant Hansenula is a virus-like particle structure, and is composed of HBsAg inserted into Hansenula lipid, and the HBsAg has 9 to 12 of 14 cysteic acids. Forming a disulfide bond; the HBsAg expressed by the recombinant Hansenula is a virus-like particle structure.
- the hepatitis B therapeutic vaccine characterized in that the inactivation condition of the inactivated recombinant Hansenula is: inactivation temperature
- the hepatitis B therapeutic vaccine is characterized in that the HBsAg expressed by the recombinant Hansenula contains the following 19 CTL epitopes: VLQAGFFLL ⁇ PFVQWFVGL, FLLTRILTK WYWGPSLYSI, SLNFLGGSPV, FLGGSPVCL, LYSIVSPF, LYSIVSPFI, PFIPLLPIF, LLLCLIFLL ⁇ LLCLIFLLV
- LLDYQGMLPV LVLLDYQGML ⁇ VLLDYQGML
- WLSLLVPFV LLVPFVQWFV GLSPTVWLSA
- SIVSPFIPLL LLPIFFCLWV.
- the hepatitis B therapeutic vaccine is characterized in that the HBcAg expressed by the recombinant Hansenula contains the following 19 CTL epitopes: SFLPSDFF, FLPSDFFPSK DFFPSIRDLL, FFPSIRDLL ⁇ SYVNV MGL, SYVNV MGLKK YVNVNMG, YVNVNMGLK, WFHISCLTF, CLTFGRETV,
- the hepatitis B therapeutic vaccine is characterized in that the dosage form of the hepatitis B therapeutic vaccine is selected from the group consisting of a prefilled injection solution, an injection solution or a lyophilized powder injection.
- the hepatitis B therapeutic vaccine is characterized in that it further contains one of HBsAg stock solution or aluminum adjuvant HBsAg.
- the present invention also provides a recombinant Hansenula polymorpha, wherein the recombinant H. polymorpha contains the sequence of SEQ 11) ⁇ «): 1 .
- the DNA sequence of SEQ ID NO: 1 is integrated into the genome of the recombinant H. polymorpha.
- the present invention also provides a recombinant Hansenula bacterium of Hansenula polymorpha, wherein the recombinant H. polymorpha contains the DNA sequence of SEQ ID NO : 3.
- the DNA sequence of SEQ ID NO: 3 is integrated into the genome of the recombinant H. polymorpha.
- the host Hansenula polymorpha of the above-mentioned recombinant Hansenula is HU-11, and the preservation number is
- the present invention provides therapeutic HBV vaccine, comprising 6-10 ⁇ ⁇ ⁇ recombinant Hansenula based on 5 ⁇ ⁇
- 108 cells may be used as adjuvants in the conventional full recombinant Hansenula cells
- the injection amount of HBsAg is maximized, and the effect of reversing the immune tolerance state of hepatitis B patients is improved.
- Inactivation of fully recombinant Hansenula cells is a potent agonist of the Dectin-1 receptor, the most important professional antigen presenting cell (DC).
- HBsAg-specific CTL cells target HBV-infected hepatocytes to release IFN- ⁇ :
- the first step of non-hepatocyte damage reduces its pool of cccDNA molecules by more than 90%, and the second step increases the process of destroying infected liver cells and triggers HBV immune reversal.
- the HBsAg expressed by the recombinant Hansenula cells as an antigen contains at least 19 CTL epitopes, which can improve the immunogenicity and reactivity of HBsAg.
- the immunogenicity and reactivity of the preferred HBsAg are further improved by preferably expressing the DNA sequence of HBsAg (SEQ ID NO: 1), preferably 19 CTL epitopes in 21 CTLs.
- HBsAg-inactivated Hansenula inactivated cells are used in combination with inactivated cells of recombinant Hansenula producing HBsAg, and HBcAg (high immunoreactivity) preferred code gene and C2 genotype, subtype double representative sequence are used.
- the HBcAg particle structure was determined according to the cryo-EM image reconstruction technique.
- the HBcAg dimers each contain four ⁇ -helices, that is, each HBcA subunit forms a dimer interface through two long ⁇ -helices;
- the alpha helix, head and tail are limited by Pros in positions 50 and 79. Deeply buried inside the dimer, there is no CTL epitope.
- the 01 helix is the so-called 3.6 helix, in which each amino acid rotates 100°, 3.6 amino acids rotates 360°, and the original 51-78 amino acids form 18 amino acids to form a 5-week ⁇ -helix; the missing 59-69 positions: ILCWGELMNLA 1 1 After the amino acids, the remaining 7 amino acids form an alpha helix that is rotated for 2 weeks.
- the other long alpha helix that forms the interface of the HBcAg dimer terminates at position 111 without any change in Gly. Therefore, this patent does not change the two long alpha helices to form a dimer interface.
- the above-mentioned 1 amino acid HBcAg can still assemble into virus-like particles (VLP) in recombinant Hansenula cells; it still maintains its thermal stability.
- VLP virus-like particles
- the results of immunoreactivity assay showed that the recombinant Hansenula HBcAg engineering strain (HC-40-25, 172 amino acids) with the above amino acid deletion was compared with the recombinant Hansenula HBcAg engineering strain (183 amino acids) HC-43 with full-length amino acids. : The former has more than three times the immunoreactivity of the latter. Based on the preferred CTL epitopes, expression sequences and recombinant Hansenula engineering strains, the present invention also optimizes the inactivation process of recombinant Hansenula cells to ensure the efficacy and safety of the vaccine.
- hepatitis B therapeutic vaccine based on the inactivated fully recombinant Hansenula cells expressing HBsAg and HBcAg provided by the present invention will have higher immunogenicity and can be better used for the treatment of hepatitis B.
- Figure 1 is a schematic diagram showing the construction process of plasmid pMPT-HBS-adw;
- Figure 2 is a physical map of the pMPT-HBC plasmid
- Figure 3 is a photomicrograph showing the PCR amplification product of the engineered strain HS604-5;
- Figure 4 is an electron micrograph of the pure (stock solution) of recombinant HBsAg obtained from recombinant Hansenula;
- Fig. 5 is a flow chart showing the steps of transformation and screening of recombinant Hansenula in the construction of recombinant Hansenula HBsAg engineering strain in Example 2.
- the Hansenula expression system consists of two main components:
- a vector system that initiates efficient expression of a foreign gene; (2) a host cell having a specific selection marker.
- the Hansenula MOX (methanol oxidase) promoter 1.5 kb
- Hansenula MOX (methanol oxidase) terminator 350 bp
- Hansenula autonomous replication sequence HARS 1.0 kb
- Saccharomyces cerevisiae uracil gene ScURA31.1kb The above 5 parts of the genetic elements are closely linked and then inserted into the pBluescrip II plasmid.
- the shuttle plasmid pMPT-02 was constructed. This is the applicant's non-exclusive proprietary technology.
- the DNA sequencing result of the URA3 gene of Hansen yeast gene disrupted host strain HU11 strain indicates that the gene is destroyed and the 31st base is inserted, and GAAGT five is inserted.
- the insertion of five bases of GAAGT produces a frameshift mutation.
- the frameshift mutation results in the replacement of all 254 codons after the 11th position.
- the probability of simultaneous reversion of five bases of GAAGT is extremely small.
- the back mutation rate of the host strain HU11 is zero; this host strain with a "0" back mutation rate is particularly advantageous for transformation screening.
- Knockout technology established ⁇ 3 ⁇ 4 ⁇ 3 auxotrophic host cell line HU-11 (CGMCC No.1218)
- the patent application filed by the patentee is CN1651570A.
- Host Hansenula HU-11 orotate-5-phosphate Decarboxylase gene (// ⁇ / ⁇ 43)
- the disrupted DNA sequence is SEQ ID NO: 5.
- the DNA sequence of the recombinant Hansenula expressing hepatitis B surface antigen (HBsAg) provided by the present invention is designed based on the HBsAg adw2 subtype, as shown in SEQ ID NO: 1, the amino acid sequence of the HBsAg is SEQ ID NO: 2.
- the DNA sequence of the recombinant Hansenula recombinant hepatitis B core antigen (HBcAg) provided by the present invention is as shown in SEQ ID NO: 3, and the amino acid sequence of the HBcAg is SEQ ID NO: 4
- a synthetic nucleotide sequence according to the sequence shown in SEQ ID NO: 1 (hereinafter referred to as HBsAg adw2 gene and constructed into a glycerol bacterium containing the HBsAg adw2 gene plasmid; the plasmid after correct sequencing is digested with EcoR I / BamH I, and digested The product was cut into 701 bp of the desired fragment DNA.
- the correct plasmid pHMPT-02 was digested with EcoR 1 1 BamH I, and the vector DNA obtained after the gel extraction was ligated to obtain the Hansenula intracellular plasmid pMPT-HBS-adw, and the plasmid pMPT-HBS was obtained.
- -adw was heat-transformed into E. coli Competent Cell JM109 (Code No. D9052), and the cells were cultured overnight. Single colonies were picked from the transformation plates, and plasmid DNA was extracted and digested with EcoR I / BamH I. The results of the digestion showed positive clones. Sequencing confirmed that the plasmid pMPT-HBS-adw was correct.
- the HBsAg adw2 gene was inserted into the multiple cloning site of the Hansenula expression system intracellular plasmid pMPT-02: between EcoR I and BamH I.
- the plasmid pMPT-HBS-adw has a full length of 7665 bp.
- a schematic diagram of the construction process of the plasmid pMPT-HBS-adw is shown in Fig. 1.
- the plasmid pMPT-HBC based on the sequence shown in SEQ ID NO: 3 was constructed in the same manner as in the construction of plasmid pMPT-HBS-adw.
- the physical map of the pMPT-HBC plasmid is shown in Figure 2.
- Hansenula hepatitis B virus surface antigen (HBsAg) engineering strain the cell electroporation technology developed by the applicant was applied, and the RC pulse: amplitude 1500V, capacitance 22 ⁇ , time constant 3-5ms electric shock 1 time, using pMPT- HBS-
- the adw plasmid was transformed into Hansenula cells of the HU-11 strain (CGMCC No. 1218) from which the URA3-gene was knocked out.
- the single colony transformants were picked from the MD selection culture plate and transferred to the MD liquid medium for serial subculture.
- the adw2 subtype HBsAg gene and the corresponding regulatory components were multi-copy and exogenously integrated into the host Hansenula cell chromosome. in. After a single colony of more than one thousand transformant single colonies, the following three steps were screened:
- the PCR technique was used to compare the electrophoretic band luminance of the HBsAg gene and the single copy number MOX (methanol oxidase) gene, and the HBsAg gene copy number was semi-quantitatively determined.
- the amplified HBsAg fragment was 800 bp in length and the amplified MOX fragment was 2000 bp in length.
- primer forward 5 '-TCAAAAGCGGTATGTCCTTCCACGT-'3
- PCR product agarose gel electrophoresis Engineering bacteria HBsAg gene amplification product size of about 800bp, Hansenula single copy gene MOX gene amplification product size of about 2000bp.
- the final screened recombinant Hansenula hepatitis B virus surface antigen (HBsAg) engineered strain was numbered HS604-5.
- Fig. 3 The electrophoresis photograph of the PCR amplification product of the engineered strain constructed and screened by the same method using the plasmid pMPT-HBC to construct the recombinant Hansenula HBsAg adw2 subtype engineering strain is shown in Fig. 3.
- Fig. 3 1 is the final recombinant Han of Marke.
- the yeast strain HBcA engineering strain is numbered HBC-40-25.
- Adw2 subtype HBsAg hepatitis B surface antigen lyophilized standard provided by Tiantan Biotechnology 10 ⁇ ⁇ Diluted with dilution solution to 1024ng/mL, 512ng/mL, 256ng/mL, 128ng/mL, 64ng/mL, 32ng/mL, 16 ng/mL, 8 ng/mL, 4 ng/mL, 2 ng/mL, Ong/mL (diluent) were 11 standard points, and the HBsAg reaction was detected by the radioimmunoassay kit.
- the recombinant strains of Hansenula engineering pilot-scale fermentation 87 hours sampling 10 OD 6. .
- the sample was diluted 200 times and the standard was simultaneously involved in the radioimmunoassay reaction.
- the expression of HBsAg antigen obtained by the ⁇ -counter auto-completed curve was 126.9 ( Ng/mL).
- the amount of HBsAg antigen expressed in recombinant Hansenula was calculated as follows:
- FIG. 4 An electron micrograph of the pure (stock solution) of the recombinant HBsAg obtained by recombining the Hansinensis HBsAg adw2 subtype engineering strain fermentation broth is shown in FIG. 4 .
- the results showed that the high purity, high concentration and virus-like particle (VLP) structure of recombinant HBsAg were stable.
- the expression of HBcAgVLP in the fermentation broth of recombinant Hansenula HBcAg engineering strain was determined by the same method. 8 ⁇ 12 g/10 8 cells.
- VLP virus-like particles
- the HBcAg protein molecule consists of a primary sequence of 183 or 185 amino acid residues, which determines the secondary, tertiary and quaternary structure of HBcAg.
- the base consists of 90 homodimers with a diameter of 30 nm and a surface with 90 condyles.
- the immunoreactivity of HBC-40-25 strain was more than three times that of the other six strong positive strains.
- the following requirements should be met: (1) The survival rate of inactivated recombinant Hansenula can be reduced; ( 2 ) Maintaining the complete recombinant Hansenula cell structure, yeast intracellular antigen (3) Maintaining the expression of HBsAg virus-like particles (VLP) and HBcAg virus-like particles (VLP) in the recombinant Hansenula cells is not stable, and the antigenic reactivity is not decreased.
- the thermal stability of HBsAg and HBcAg virus-like particles (VLP) in the inactivated recombinant Hansenula cells has become the first problem to be solved.
- the extracellular HBsAg and HBcAg antigen reactivity was extremely low over the entire temperature and time range of the inactivation assay, indicating that the intracellular VLP did not leak, keeping the inactivated recombinant Hansenula cells intact.
- the survival rate of inactivated cells was as low as 50,000 at 56 ° C for 3 h. This provides a basis for optimizing the conditions for inactivation of recombinant Hansenula cells.
- HBsA and HBcAg-specific CTL T cells trigger immune reversal in non-cell damage
- HBV capsid antigen (Pre-Sl-Pre-S2-HBsAg) does not repeat CTL epitopes A total of 23.
- the HBsAg amino acid sequence of the present application contains the following 19 CTL epitopes: VLQAGFFLL, PFVQWFVGL, FLLLILLTI, WYWGPSLYSI, SLNFLGGSPV, FLGGSPVCL, LYSIVSPF, LYSIVSPFI, PFIPLLPIF, LLLCLIFLL LLCLIFLL V LLDYQGMLPV, LVLLDYQGML, VLLDYQGML, WLSLLVPFV, LLVPFVQWFV, GLSPTVWLSA, SIVSPFIPLL, LLPIFFCLWV.
- the HBcAg amino acid sequence of the present application contains the following 19 CTL epitopes: SFLPSDFF, FLPSDFFPSK DFFPSIRDLL, FFPSIRDLL ⁇ SYVNVNMGL, SYVNV MGLKK YVNVNMG, YVNV MGLK, WFHISCLTF, CLTFGRETV, VLEYLVSFGV, EYLVSFGVW, EYLVSFGVWI, AYRPPNAPI, AYRPPNAPIL, APILSTLPE, ILSTLPETTV, STLPETTVVRR , RGRSPRRRTPc
- the hepatitis B therapeutic vaccine product provided by the invention is preferably a prefilled injection solution:
- Pre-filled syringe 1 needle 1 box easy to use, easy to use and essential to use, disposable syringe, can not be reused. There is no need for a separate syringe for vaccination, which prevents the use of glass syringes to completely infect infections or spread infectious diseases, and improper needle selection affects the inoculation effect, avoiding the risk of repeated use of disposable syringes.
- the pMPT-HBS-adw plasmid (i.e., the expression vector comprising the SEQ ID NO: 1) constructed based on the SEQ ID NO: 1. Construction of the plasmid pMPT-HBS-adw includes the following:
- the HBsAg adw2 gene was synthesized according to our designed sequence of SEQ ID NO: 1; and a glycerol strain containing the HBsAg adw2 gene plasmid was constructed and named MC407B-16.
- the correctly sequenced MC407B-16 plasmid was digested with EcoR II BamH I, and the digested product was recovered by TaKaRa PCR Fragment Recovery Kit (Code No. D301).
- the 701 bp target fragment DNA was called Inset.
- the plasmid pHMPT-02 was digested with EcoR I / BamH I, and the vector DNA obtained after the gel extraction was called Vector DNA6.
- Inset DNA6 was ligated with Vector DNA6 using Solution in TaKaRa DNA Ligation Kit (Code No. D6022), and then thermally transformed into E. coli Competent Cell JM109 (Code No. D9052), and the plate was coated overnight to culture the cells. Single colonies were selected from the transformation plates, and plasmid DNA was extracted and digested with EcoR I / BamH I. The results showed that: MC407A+B+C+D-77 ⁇ 80 were positive clones.
- the plasmid MC407A+B+C+D-77 was used with primers RV-M, Ml 3 -47, MC407P1 , MC407P2, respectively.
- the MC407BR11 was sequenced and the plasmid pMPT-HBS-adw was confirmed to be correct.
- Recombinant Hansenula Hepatitis B vaccine transformation and screening diagram The transformation and screening process of recombinant Hansenula is shown in Figure 5 - specifically
- the pMPT-HBS-adw plasmid was transformed into the URA3-auxotrophic Hansenula cell line HU-11 (CGMCC ⁇ . 1218) of the host cell by cell electroporation.
- the culture medium was selected using a selection medium (MD liquid medium).
- the single colony transformants were picked from the MD selection culture plate and transferred to the MD liquid medium for continuous subculture.
- the adw2 subtype HBsAg gene and the corresponding regulatory components were multi-copy and exogenously integrated into the host Hansenula cell chromosome. in.
- Colonies with fast growth rate of bacteria were selected. After detecting the brightness of HBsAg gene band by PCR, colonies with a large number of copies were selected, and single colonies were shake-cultured in a selective medium, and 20 400 generations were successively subcultured;
- radioimmunoassay or radioimmunoassay was used to determine the expression level of HBsAg released after disruption of transformant cells;
- the clones screened by the step (2) were cultured in YPD complete medium for 48 hours, and then transferred to a selection medium for cloning and culture, and HBsAg gene copy number was detected by quantitative PCR, and HBsAg expression level was detected by RIA.
- step (3) Based on the test result of step (3), a primary strain of genetically stabilized recombinant Hansenula HBsAg engineering bacteria was selected.
- Example 3 30 liters of pilot fermentation (recombinant Hansenula HBcAg engineering strain and recombinant Hansenula HBsAg engineering strain using the same fermentation process)
- the feeding operation of the growth phase is to be significantly reduced when the dissolved oxygen is consumed, and the basic medium is consumed when it starts, and The increase of the consumption of the basic medium gradually increases the flow acceleration, and the addition is completed 2-3 hours before the dissolved oxygen rises.
- the dissolved oxygen begins to rise after the end of the flow.
- the methanol-inducing solution is started to be added, and the methanol concentration is controlled to 3-5%.
- the flow acceleration is controlled by the methanol detection flow controller.
- Methanol addition was stopped 2-3 hours before the end of the fermentation to reduce methanol residue during cell harvesting.
- Biotin was first dissolved in 10 ml of 50% isopropanol, and then dissolved in Thiamin HC1, and then dissolved in deionized water to a volume of 100 ml.
- the weighed reagent is placed in a cleaned triangular flask, and an appropriate amount of deionized solution is added to dilute the water to a volume of 50 ml t or more.
- the weighed reagent was placed in a cleaned triangular flask, dissolved in deionized water and dissolved to a volume of 1600 ml.
- HBsAg Purification, HBsAg and HBcAg use the same purification process, taking HBsAg as an example, the process is as follows:
- the above harvested cells can be crushed by a homogenizer to release HBsAg; 0.22 ⁇
- the cell filter was removed by filtration through a pore filter; the small molecular impurities were removed by ultrafiltration with a 300 ⁇ ultramicrofilter; HBsAg was extracted by silica gel adsorption treatment; and finally purified by butyl agarose hydrophobic chromatography.
- VLP virus-like particle
- Recombinant Hansenula HBsAg engineered bacteria (HS604-5 strain) Cell culture was induced by fermentation or shake flask. The cells were washed three times with centrifugation in phosphate buffered saline (PBS) and the precipitated Hansenula was suspended in a calculated volume of PBS. The cells were counted using OD 6 () Qnm , diluted to 10 OD 6QQnm / ml in PBS, 2 ml per tube; 2 test tubes were broken and not broken in each test group; 32 test tubes were prepared in 16 test groups.
- PBS phosphate buffered saline
- the inactivated recombinant Hansenula should be cultured for 3 days at 37 ° C in a chloramphenicol complete medium agar dish; the survival rate is counted.
- Heat-killed Hansenula is stored at 4 degrees Celsius for further use.
- Bo wen DG et.al Intrahepatic immunity: a tale of two sites? Bo wen DG et.al, Trends Immunol. 2005, 26(10): 512-7.
- Haibin Huang et.al Robust Stimulation of Humoral and Cellular Immune Responses Following Vaccination with Antigen -Loaded ⁇ -Glucan Particles, 2010, MBio.asm.org, 1 (3): 1-7.
- CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection; J Virol. 2003 Jan; 77(l): 68-76.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17769369.4A EP3434282A4 (en) | 2016-03-25 | 2017-03-16 | THERAPEUTIC VACCINE AGAINST HEPATITIS B BASED ON AN INACTIVATED WHOLE RECOMBINANT HANSENULA CELL EXPRESSING HBSAG AND HBCAG |
EA201892172A EA201892172A1 (ru) | 2016-03-25 | 2017-03-16 | Вакцина для лечения гепатита b на основе инактивированных цельных рекомбинантных клеток hansenula, которые экспрессируют hbsag и hbcag |
US16/088,217 US11191829B2 (en) | 2016-03-25 | 2017-03-16 | Hepatitis B treatment vaccine base on inactivated whole recombinant Hansenula polymorpha cells which expresses HBsAg and HBcAg |
SG11201808267SA SG11201808267SA (en) | 2016-03-25 | 2017-03-16 | Hepatitis b treatment vaccine based on inactivated whole recombinant hansenula cell which expresses hbsag and hbcag |
JP2019500716A JP6818122B2 (ja) | 2016-03-25 | 2017-03-16 | HBsAg及びHBcAgを発現する失活化全組換えハンセヌラ・ポリモルファ細胞によるB型肝炎治療ワクチン |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610176389.4 | 2016-03-25 | ||
CN201610176389.4A CN105727279B (zh) | 2016-03-25 | 2016-03-25 | 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017162092A1 true WO2017162092A1 (zh) | 2017-09-28 |
Family
ID=56251451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/076936 WO2017162092A1 (zh) | 2016-03-25 | 2017-03-16 | 基于表达HBsAg和HBcAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11191829B2 (zh) |
EP (1) | EP3434282A4 (zh) |
JP (1) | JP6818122B2 (zh) |
CN (1) | CN105727279B (zh) |
EA (1) | EA201892172A1 (zh) |
SG (1) | SG11201808267SA (zh) |
WO (1) | WO2017162092A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1651570A (zh) * | 2004-09-30 | 2005-08-10 | 天津博荟生物技术有限公司 | 一种重组多形汉逊酵母菌及其构建方法与应用 |
US20060292118A1 (en) * | 2002-11-22 | 2006-12-28 | Shunichi Kuroda | Hollow nanoparticles of protein and drug using the same |
CN102038948A (zh) * | 2009-10-10 | 2011-05-04 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
CN1107681C (zh) * | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
CA2422506A1 (en) * | 2000-09-08 | 2002-03-14 | Epimmune Inc. | Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
CN101314761B (zh) * | 2007-05-31 | 2012-05-30 | 上海生物制品研究所有限责任公司 | 高拷贝表达重组乙肝表面抗原的毕赤酵母及其制法和应用 |
CN102462840B (zh) * | 2010-11-09 | 2014-03-19 | 南通生物科技园开发投资有限公司 | 乙肝治疗性疫苗 |
CN102226154B (zh) * | 2011-05-12 | 2013-02-06 | 中国科学院微生物研究所 | 具有双重筛选标记的多形汉逊酵母菌及其应用 |
CN104232661A (zh) * | 2013-06-08 | 2014-12-24 | 北京天坛生物制品股份有限公司 | 重组dna序列、酵母菌、乙肝表面抗原制备方法及疫苗 |
CN105727280B (zh) * | 2016-03-25 | 2021-01-19 | 汪和睦 | 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗 |
CN105797151A (zh) * | 2016-03-25 | 2016-07-27 | 汪和睦 | 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗 |
-
2016
- 2016-03-25 CN CN201610176389.4A patent/CN105727279B/zh active Active
-
2017
- 2017-03-16 EP EP17769369.4A patent/EP3434282A4/en not_active Ceased
- 2017-03-16 JP JP2019500716A patent/JP6818122B2/ja active Active
- 2017-03-16 WO PCT/CN2017/076936 patent/WO2017162092A1/zh active Application Filing
- 2017-03-16 US US16/088,217 patent/US11191829B2/en active Active
- 2017-03-16 EA EA201892172A patent/EA201892172A1/ru unknown
- 2017-03-16 SG SG11201808267SA patent/SG11201808267SA/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292118A1 (en) * | 2002-11-22 | 2006-12-28 | Shunichi Kuroda | Hollow nanoparticles of protein and drug using the same |
CN1651570A (zh) * | 2004-09-30 | 2005-08-10 | 天津博荟生物技术有限公司 | 一种重组多形汉逊酵母菌及其构建方法与应用 |
CN102038948A (zh) * | 2009-10-10 | 2011-05-04 | 复旦大学 | 一种控制乙型肝炎病毒持续性感染的疫苗 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3434282A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019510089A (ja) | 2019-04-11 |
EP3434282A1 (en) | 2019-01-30 |
CN105727279A (zh) | 2016-07-06 |
CN105727279B (zh) | 2019-01-15 |
US20200376115A1 (en) | 2020-12-03 |
SG11201808267SA (en) | 2018-11-29 |
JP6818122B2 (ja) | 2021-01-20 |
EA201892172A1 (ru) | 2019-07-31 |
EP3434282A4 (en) | 2019-10-30 |
US11191829B2 (en) | 2021-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021182922A (ja) | B型肝炎ウイルスに対するワクチン | |
Sominskaya et al. | Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes | |
EP1294893B1 (en) | Modification of hepatitis b core antigen | |
WO2017162091A1 (zh) | 基于表达HBsAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗 | |
Wang et al. | Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice | |
JP2021073261A (ja) | 組換えハンセヌラ・ポリモルファによる高用量b型肝炎ワクチン | |
EP2198020A1 (en) | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use | |
CN101309931B (zh) | 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗 | |
WO2017162092A1 (zh) | 基于表达HBsAg和HBcAg的失活全重组汉逊酵母细胞的乙肝治疗疫苗 | |
CN102199217B (zh) | 乙型肝炎病毒多表位融合蛋白及其制备方法和应用 | |
Sanyal et al. | A review of multiple approaches towards an improved hepatitis B vaccine | |
Rizzetto et al. | Progress in the prevention and control of viral hepatitis type B: closing remarks | |
EP2484343A1 (en) | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization | |
CN107648602B (zh) | 二价乙肝疫苗及其制备方法 | |
Guan et al. | Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine | |
CN117903321A (zh) | 一种结核病毒样颗粒及其制备方法与应用 | |
WO2005117960A1 (fr) | Vaccin adn contre le sras et procede de preparation de celui-ci, utilisation de gene glycoproteine spicule (spike) des coronavirus pour vaccin | |
Schumann | Hepatitis B virus specific adoptive immune transfer in living liver donation and characterization of a prophylactic/therapeutic vaccine against Hepadnaviral infection | |
JP2014500875A (ja) | B型肝炎の予防及び治療のためのdnaワクチン組成物 | |
Shih | Virion Secretion of Naturally Occurring Core Antigen Variants of Human Hepatitis B Virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2019500716 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201892172 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017769369 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2017769369 Country of ref document: EP Effective date: 20181025 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17769369 Country of ref document: EP Kind code of ref document: A1 |